VK

Vipin Kansal

Active Director Director DIN 00857240
DIN 00857240 First appointment Dec 2005 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2005
Shareholding value •••• Premium profile

About Vipin Kansal

Data last updated:

Vipin Kansal is a Director at Voluenta Pharmaceuticals Private Limited (since 2005). The company operates in Pharma. Voluenta Pharmaceuticals Private Limited reported revenue of ₹72 Lakh (FY 2025).

DIN 00857240
Primary Designation Director
Industry Pharma
First Appointment 29 Dec 2005
Oldest Company Age 20 yrs
Largest company Voluenta Pharmaceuticals Private Limited · ₹72 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Dec 20052005₹72 Lakh (FY 2025)Active

Board colleagues of Vipin Kansal

Directorship timeline

Open interactive timeline →
Voluenta Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Vipin Kansal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vipin Kansal

Vipin Kansal currently holds 1 directorship: Voluenta Pharmaceuticals Private Limited (Director, since 29 Dec 2005, revenue ₹72 Lakh (FY 2025)).

Vipin Kansal was first appointed on 29 Dec 2005 as Director at Voluenta Pharmaceuticals Private Limited.

The current boards of Vipin Kansal's companies include Nirbhay Kansal (Voluenta Pharmaceuticals Private Limited), Vinay Kansal (Voluenta Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available